A Predictive Response Signature to Infliximab Treatment in Ulcerative Colitis
Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to respond to treatment. Consequently, about 40% of patients do not respond. This study analyzed mucosal gene expression from patients enrolled in ACT1 to provide a predictive response signature for infliximab treatment.
Provenance — who produced it, who reused it
Linked to 19 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Oncostatin M drives intestinal inflammation and predicts respons... 2017 · 798 cites
- IL-1-driven stromal–neutrophil interactions define a subset of p... 2021 · 289 cites
- Conserved transcriptomic profile between mouse and human colitis... 2019 · 134 cites
- IL-7 receptor influences anti-TNF responsiveness and T cell gut... 2019 · 132 cites
- Quantification of biological network perturbations for mechanist... 2014 · 104 cites
14 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently